TNF and type 1 diabetes mellitus: The T1D consortium has received a qualification opinion from the European Medicines Agency on the use of islet autoantibodies as enrichment biomarkers [54], participation in the workshop for outlining the path for using tumor necrosis factor-alpha (TNF-α) inhibitors in pivotal clinical trials in T1D [55], and supported evidence generation for the use of C-peptide as a surrogate end point in clinical trials [56].